In a review article, Yamanoi et al. [18] proposed that reduced expression of αGlcNAc on MUC6 in premalignant lesions of the stomach, pancreas (IPMN), and esophagus (Barrett’s esophagus) may serve as an early event marking tumor progression. Here, MUC6 is linked to esophageal adenocarcinoma.